Market revenue in 2023 | USD 524.3 million |
Market revenue in 2030 | USD 1,337.7 million |
Growth rate | 14.3% (CAGR from 2023 to 2030) |
Largest segment | Therapeutics |
Fastest growing segment | Diagnostics |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Diagnostics, Therapeutics |
Key market players worldwide | Roche, Siemens Healthineers AG ADR, Janssen Pharmaceuticals, Illumina Inc, Quest Diagnostics Inc, 23andMe Holding Co Class A, NeoDiagnostix, International Business Machines Corp, Myriad Genetics Inc, Medtronic PLC, GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Dakota Software, Biogen Inc, Qiagen NV, ImmunityBio Inc Ordinary Shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to precision medicine market will help companies and investors design strategic landscapes.
Therapeutics was the largest segment with a revenue share of 81.33% in 2023. Horizon Databook has segmented the Sweden precision medicine market based on diagnostics, therapeutics covering the revenue growth of each sub-segment from 2018 to 2030.
The market for precision medicine in Sweden is expanding owing to various factors such as increasing focus of the government on implementing PM in its healthcare system, growing prevalence of target diseases such as cancer, and rising awareness regarding the benefits of personalized medicine.
The Swedish government initiated Genomic Medicine Sweden (GMS) in 2017 to enable access to PM across the country. Under this initiative, the major university healthcare regions and medical faculties agreed to collaborate. The focus of this initiative was to implement genomic testing for patients with rare diseases, cancer, & infectious diseases and increase access to personalized medicine.
Furthermore, in February 2023, NEOGAP Therapeutics received approval from the Swedish Medical Products Agency to commence a clinical trial for its personalized cell therapy targeting colorectal cancer. The company intended to initiate the phase I/IIa trial in 2023.
Horizon Databook provides a detailed overview of country-level data and insights on the Sweden precision medicine market , including forecasts for subscribers. This country databook contains high-level insights into Sweden precision medicine market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account